<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01516567</url>
  </required_header>
  <id_info>
    <org_study_id>Inter B-NHL Ritux 2010 Phase 2</org_study_id>
    <secondary_id>2010-019224-31</secondary_id>
    <nct_id>NCT01516567</nct_id>
    <nct_alias>NCT01595048</nct_alias>
  </id_info>
  <brief_title>Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation</brief_title>
  <official_title>Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase II Trial of DA-EPOCH-Rituximab in PMLBL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II trial to determine the efficacy of Dose Adjusted-EPOCH-Rituximab regimen in children&#xD;
      and adolescent with primary mediastinal large B cell lymphoma in terms of event free&#xD;
      survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2012</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>36 months</time_frame>
    <description>Minimum time to death from any cause, presence of viable cells in residue after 6th DA-EPOCH course, relapse, progressive disease, or second malignancy measured from registration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>Acute toxicity during treatment according to NCI-CTC V4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>Long term toxicity, especially immune reconstitution, cardiac toxicity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Primary Mediastinal Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>DA-EPOCH-R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 courses of Dose Adjusted-EPOCH-Rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab</intervention_name>
    <description>6 courses of Dose Adjusted-EPOCH-Rituximab Rituximab 375 mg/m² i.v.: one injection at each of the 6 courses of EPOCH.</description>
    <arm_group_label>DA-EPOCH-R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven Primary Mediastinal Large B-Cell Lymphoma (PMLBL).&#xD;
&#xD;
          -  PMLBL without central nervous system (CNS) involvement.&#xD;
&#xD;
          -  6 months to less than 18 years of age at the time of consent.&#xD;
&#xD;
          -  Males and females of reproductive potential must agree to use an effective&#xD;
             contraceptive method during the treatment, and after the end of treatment: during&#xD;
             twelve months for women, taking into account the characteristics of rituximab&#xD;
&#xD;
          -  Complete initial work-up within 8 days prior to treatment that allows definite&#xD;
             staging.&#xD;
&#xD;
          -  Able to comply with scheduled follow-up and with management of toxicity.&#xD;
&#xD;
          -  Signed informed consent from patients and/or their parents or legal guardians&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Follicular lymphoma, mucosa-associated lymphoid tissue (MALT) and nodular marginal&#xD;
             zone&#xD;
&#xD;
          -  PMLBL patients with CNS involvement&#xD;
&#xD;
          -  Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ&#xD;
             transplantation, previous malignancy of any type, or known positive HIV serology.&#xD;
&#xD;
          -  Evidence of pregnancy or lactation period.&#xD;
&#xD;
          -  There will be no exclusion criteria based on organ function.&#xD;
&#xD;
          -  Past or current anti-cancer treatment except corticosteroids during less than one&#xD;
             week.&#xD;
&#xD;
          -  Tumor cell negative for CD20&#xD;
&#xD;
          -  Prior exposure to rituximab.&#xD;
&#xD;
          -  Severe active viral infection, especially hepatitis B.&#xD;
&#xD;
          -  Hepatitis B carrier status history of hepatitis B virus (HBV) or positive serology.&#xD;
&#xD;
          -  Participation in another investigational drug clinical trial.&#xD;
&#xD;
          -  Patients who, for any reason, are not able to comply with the national legislation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine PATTE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Gustave Roussy, Villejuif, FRANCE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas GROSS, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Oncology Group, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children Oncology Group Operations centres</name>
      <address>
        <city>Monrovia</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2nd Dept. of Pediatrics Semmelweis Univ.</name>
      <address>
        <city>Budapest</city>
        <zip>1094</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associazione Italiana di Ematologia ed Oncologia Pediatrica</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emma Children's Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rectorat of Medical University</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedad Española de Hematología y Oncología Pediátricas</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.igr.fr</url>
    <description>Institute Gustave Roussy web site</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 19, 2012</study_first_submitted>
  <study_first_submitted_qc>January 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

